Federico Durbano

ASST Melegnano e della Martesana Italy

Federico Durbano is a Doctor of Medicine (MD) with a specialization in Psychiatry. He has worked at various hospitals, including Milan’s Ospedale Maggiore Policlinico, Treviglio, Melegnano, and Fatebenefratelli, where he achieved significant career milestones. He is currently the director of the Mental Health and Addictions Department at ASST Melegnano e della Martesana, Milan, Italy. Dr. Durbano has had teaching assignments at the University of Milan (Nursing School). He is a member of the Italian Society of Psychiatry. He has attended more than 100 local and national congresses and courses as an invited speaker and published over 180 papers and books. He is also a technical advisor to the court in forensic psychiatry.

Federico Durbano

11books edited

9chapters authored

Latest work with IntechOpen by Federico Durbano

What if the substances once feared, celebrated, and banned could become tools for healing? After decades of silence and stigma, psychedelic science is experiencing an extraordinary renaissance. From ancient shamanic rituals with ayahuasca and peyote to 20th-century laboratory discoveries like LSD and MDMA, these compounds have always stood at the crossroads between spirituality, neuroscience, and cultural upheaval. This book explores that journey: the rise, fall, and rebirth of psychedelics in medicine. It traces their traditional uses, the scientific enthusiasm of the 1950s and 60s, the abrupt prohibition that followed, and the cautious reopening of research in the last three decades. Today, studies reveal how psychedelics act on brain networks involved in self-awareness and emotion, opening windows of neuroplasticity that may radically transform the treatment of depression, PTSD, addictions, and end-of-life anxiety. However, the promise comes with complexity. Psychedelics are “molecules of meaning”: capable of dissolving the ego, amplifying emotions, and reshaping perception, effects that can heal or harm depending on context, preparation, and guidance. Their therapeutic potential is matched by ethical, legal, and cultural challenges: ensuring informed consent, respecting traditional knowledge, regulating clinical use, and preventing misuse. Through a rigorous and balanced overview of the most studied substances, psilocybin, LSD, MDMA, ayahuasca, mescaline, ibogaine, and ketamine, this book examines mechanisms of action, clinical evidence, risks, limitations, and future directions. It also addresses the emerging role of psychedelics in treating addiction, where early findings highlight their ability to disrupt entrenched behavioral patterns and support long-term change. Neither panacea nor peril, psychedelics invite us to rethink mental health, consciousness, and the relationship between brain, mind, and society. This book provides the knowledge needed to navigate a rapidly evolving field with curiosity, but while maintaining critical thinking and scientific integrity.

Go to the book